Haleon's stock drops as Deutsche Bank warns of changing sales channels and weakening consumer trends.
ByAinvest
Thursday, Jan 22, 2026 9:32 am ET1min read
HLN--
Haleon shares dropped after Deutsche Bank reiterated its "sell" rating, citing concerns over a shift in consumer trends and weakening demand for the company's OTC health products. Analysts trimmed their target price to 335p and cut earnings estimates for 2026 by 1.8%. They highlighted a potential erosion of margins due to changing sales channels, particularly in the US, and softening demand in cold and flu categories.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet